Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …

Alternatively polarized macrophages (Mϕ) shape the microenvironment of hepatocellular
carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib …

Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …

Sorafenib, a multikinase inhibitor, is a first-line treatment for advanced hepatocellular
carcinoma, but its long-term effectiveness is limited by the emergence of resistance …

Accumulating evidence suggests that regulatory T cells (Tregs) and myeloid-derived
suppressor cells (MDSC) are elevated in cancer patients and tumor-bearing hosts, and that …

Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for
advanced HCC, Sorafenib, offers limited survival benefits. Here we assessed whether …

Background There is an urgent need for effective treatments for hepatocellular carcinoma
(HCC). Immunotherapy is promising especially when combined with traditional therapies …

Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for
advanced hepatocellular carcinoma (HCC) but provides limited survival benefits. Recently …

The multikinase inhibitor sorafenib is the only effective drug in advanced cases of
hepatocellular carcinoma (HCC). However, response differs among patients and …

Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …